Skip to main content

ProKidney Corp.

corporate_fare Company Profile

ProKidney Corp.

PROK·NASDAQ·Life Sciences·CIK 0001850270

PROKIDNEY CORP. is a late-clinical-stage biotechnology company focused on developing a first-in-class, autologous cell therapy to preserve kidney function in patients with advanced chronic kidney disease (CKD) and diabetes. The company aims to shift the treatment of CKD from managing kidney failure to preserving kidney function. Its lead product candidate, rilparencel, is the only cell therapy currently in Phase 3 clinical study for advanced CKD and type 2 diabetes. Rilparencel is a personalized product containing autologous Selected Renal Cells (SRC), which are prepared from a patient's own kidney cells. These SRC are formulated as rilparencel and reinjected into the patient's kidneys through a minimally invasive outpatient procedure. Since rilparencel uses a patient's own cells, it eliminates the need for lifelong immunosuppressive therapies typically required after receiving a kidney transplant from another donor. The company's technology involves expanding and selecting a patient's kidney cells to preserve kidney function that is being lost due to chronic disease. The process starts with a small biopsy of a patient's diseased kidney sent to PROKIDNEY CORP.'s manufacturing facility. There, tissue from the biopsy is processed to isolate SRC, which are then formulated into a personalized product for reinjection into the damaged kidney(s). Clinical studies to date suggest rilparencel can positively impact kidney function by stabilizing the estimated glomerular filtration rate (eGFR) or slowing its decline in patients with CKD and diabetes. CKD is categorized into five stages, from mild (Stage 1) to severe (Stage 5 or kidney failure). Over 37 million people in the United States are estimated to suffer from CKD. PROKIDNEY CORP. is initially developing rilparencel in the United States for patients with moderate to severe CKD and type 2 diabetes, a population exceeding one million people.

ProKidney Corp. (NASDAQ:PROK) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 14 items for PROK at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 8/10. Across its 14 most recent items scored 7 or higher, the top rating is 9/10, with 6 rated 8 or above. Recent SEC coverage for PROK spans 10-Q, 8-K, S-3, 10-K.

Recent high-impact activity:

  • ProKidney 10-Q: $141.9M Cash Won't Fund 12 Months, Going Concern Doubt
  • Q3 Loss Widens to $51.8M as Cash Drops $39.7M; PROACT 1 Readout Set for Q2 2027
  • ProKidney Discloses $141.9M Cash, Runway Into Mid-2027, and Lifted PROACT 1 Enrollment Target
  • ProKidney Files $650M Shelf and $200M Jefferies ATM Weeks After Going-Concern Warning
  • ProKidney Q2 Loss Widens to $48M as Trial Costs Surge; Enrollment Milestone Hit

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$893K
Net Income
-$68.99M
Op. Cash Flow
-$120.12M
Free Cash Flow
-$135.31M
Operating Income
-$165.01M
Cash & Equivalents
$108.54M
Debt / Equity
0.00×
Net Margin
-77.25×
Source: 10-K · filed 2026-03-18 · accession 0001193125-26-113881

Short Interest & Short Volume

22.51 days to cover

FINRA reported short interest of 24,336,295 shares in PROK as of the October 30, 2026 settlement, a 0.9% decrease from the prior period — about 22.5 days to cover at its recent average daily volume. On November 20, 2026, 73.0% of PROK volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)24,336,295 shares as of October 30, 2026
Change vs prior period▼ 0.9%
Days to cover22.51 at avg daily volume of 1,080,929
Daily short volume (FINRA facilities)73.0% of 1,222,536 shares on November 20, 2026
5-day average short volume74.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for PROK, detected from its recent SEC filings · based on capital-structure filings through 2026-11-12.

1 recent capital raiseATM program1 shelf registration

ATM Prospectus Supplement Filed · No Shares Sold Yet

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with P →
$1.03 -0.94% today
52-week range · as of 2026-11-12 $0.8702 – $2.88
Market cap
$315.15M
Volume
1.9M (1.3× avg)
3-mo avg 1.4M
Live data · 2026-11-21 19:36 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PROK - Latest Insights

PROK
Nov 12, 2026, 4:16 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.15
Real-time Price: $1.03 info
Change: -$0.1198 (-10%) info
Market Cap: $315.15M info
PROK
Nov 12, 2026, 4:10 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.15
Real-time Price: $1.03 info
Change: -$0.1198 (-10%) info
Market Cap: $315.15M info
PROK
Nov 09, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.14
Real-time Price: $1.03 info
Change: -$0.1098 (-10%) info
Market Cap: $315.15M info
PROK
Oct 29, 2026, 4:46 PM EDT
Filing Type: S-3
Importance Score:
8
Price at Filing: $1.46
Real-time Price: $1.03 info
Change: -$0.4298 (-29%) info
Market Cap: $315.15M info
PROK
Aug 10, 2026, 4:22 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $1.64
Real-time Price: $1.03 info
Change: -$0.6098 (-37%) info
Market Cap: $315.15M info
PROK
Aug 10, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.64
Real-time Price: $1.03 info
Change: -$0.6098 (-37%) info
Market Cap: $315.15M info
PROK
Aug 10, 2026, 4:10 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.64
Real-time Price: $1.03 info
Change: -$0.6098 (-37%) info
Market Cap: $315.15M info
PROK
May 15, 2026, 11:49 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.61
Real-time Price: $1.03 info
Change: -$0.5787 (-36%) info
Market Cap: $315.15M info
PROK
May 15, 2026, 11:47 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.61
Real-time Price: $1.03 info
Change: -$0.5787 (-36%) info
Market Cap: $315.15M info
PROK
May 15, 2026, 11:45 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.61
Real-time Price: $1.03 info
Change: -$0.5748 (-36%) info
Market Cap: $315.15M info
PROK
Mar 18, 2026, 4:01 PM EDT
Filing Type: 10-K
Importance Score:
7
Price at Filing: $2.08
Real-time Price: $1.03 info
Change: -$1.05 (-50%) info
Market Cap: $315.15M info
PROK
Mar 18, 2026, 4:00 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.08
Real-time Price: $1.03 info
Change: -$1.05 (-50%) info
Market Cap: $315.15M info
PROK
Feb 02, 2026, 4:04 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.04
Real-time Price: $1.03 info
Change: -$1.01 (-50%) info
Market Cap: $315.15M info
PROK
Jan 12, 2026, 7:54 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.38
Real-time Price: $1.03 info
Change: -$1.35 (-57%) info
Market Cap: $315.15M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets